The “age of genomic health/medicine screening” is being introduced into prenatal care
through the prenatal genetic screening programs. The discussion and rigor that is
expected by the industry and the provider for this genomic screening—in both the pre-
and post-test arenas—for a patient-informed consent process is extensive.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Obstetrics and Gynaecology CanadaAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Screening for Disease.(Available at:) (Accessed on March 30, 2017)
- Alberta Prenatal Record Part 1 and 2 [Internet].(Available at:) (Accessed on March 30, 2017)
- Stakeholder attitudes and needs regarding cell-free DNA testing.Curr Opin Obstet Gynecol. 2016; 28: 125-131
Article info
Publication history
Published online: August 17, 2017
Accepted:
May 10,
2017
Received:
March 31,
2017
Footnotes
Competing interests: None declared.
Identification
Copyright
© 2017 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- CorrectionJournal of Obstetrics and Gynaecology Canada Vol. 40Issue 9
